Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 3Melanoma 2Lung Neoplasms 2Neoplasms 1Kidney Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 9Cyclophosphamide 6fludarabine phosphate 4aldesleukin 3Radiotherapy 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cetuximab 3temsirolimus 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2fludarabine 2entinostat 2durvalumab 2belinostat 2atezolizumab 2Sirolimus 2Paclitaxel 2Methods 2Metformin 2Irinotecan 2Interferon-alpha 2Bortezomib 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1tremelimumab 1tocilizumab 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × AZD 6244 × Breast × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡